Salem Radio Network News Saturday, November 27, 2021


Roche’s Gavreto wins conditional EU approval in a form of lung cancer

ZURICH (Reuters) – Roche’s Gavreto has won conditional European Commission approval for treating adults with a form of non-small cell lung cancer, the Swiss drugmaker said on Friday.

Gavreto, known generically as pralsetinib, is the first and only precision medicine approved in the EU for first-line treatment of people with RET fusion-positive advanced NSCLC. Around 37,500 people are diagnosed with RET fusion-positive NSCLC worldwide each year, it said in a statement.

(Reporting by Michael Shields; Editing by Riham Alkousaa)


Editorial Cartoons

View More »

Steve Breen
Sun, Nov 21, 2021